Development of the molecular target therapy for oral squamous cell carcinoma by tumor angiogenesis inhibit.
Project/Area Number |
21890168
|
Research Category |
Grant-in-Aid for Research Activity Start-up
|
Allocation Type | Single-year Grants |
Research Field |
Surgical dentistry
|
Research Institution | Yamaguchi University |
Principal Investigator |
ITASHIKI Yasutaka Yamaguchi University, 医学部附属病院, 医員研究 (70530236)
|
Project Period (FY) |
2009 – 2010
|
Project Status |
Completed (Fiscal Year 2010)
|
Budget Amount *help |
¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2010: ¥1,235,000 (Direct Cost: ¥950,000、Indirect Cost: ¥285,000)
Fiscal Year 2009: ¥1,365,000 (Direct Cost: ¥1,050,000、Indirect Cost: ¥315,000)
|
Keywords | Bevacizumab / S-1 / 血管新生阻害 / アポトーシス / ヒト口腔細胞株 / 5-FU / ベバシズマブ / TS-1 / VEGF / 腫瘍新生血管 / Ki67 / ヒト口腔癌細胞株 / ベバチズマブ / VEGFR1 / VEGFR2 |
Research Abstract |
Because the combination of bevacizumab and S-1 which was a 5-FU-based anticancer agent which was the molecular target drug of the vascularization repressor showed a significant antitumor effect in the implanted nude mouse of the oral squamous cell carcinoma cell, HSC-2, it was suggested that it was with new Tumor dormancy therapy for oral cancer.
|
Report
(3 results)
Research Products
(6 results)